Home Contact Sitemap login Checkout

BioAlberta
  • Home
  • About
    • About
    • The BioAlberta Team
    • From The President
    • What We Do
    • Board of Directors
    • Committees
    • Industry Partners
    • Hall Of Fame
  • Boosting Biotech
  • Industry Facts
    • Industry Facts
    • Medical Technology & Devices
    • Health Biotechnology & Pharmaceuticals
    • Agricultural Biotechnology
    • Industrial Biotechnology
    • Functional Foods & Natural Health Products
    • Environmental Biotechnology
    • Industry Terms
  • Events
    • Events
    • Annual Events & Activities
    • Archived Events
      • Archived Events
      • 2020 Events
      • 2019 Events
      • 2018 Events
      • 2017 Events
      • 2016 Events
      • 2015 Events
      • 2014 Events
  • News
    • News
    • Archived News
      • Archived News
      • 2020 News
      • 2019 News
      • 2018 News
      • 2017 news
      • 2016 News
      • 2015 News
      • 2014 News
  • Member Area
    • Member Area
    • Member Marketplace
    • Join Now
    • Member Benefits
      • Member Benefits
      • How To Access Member Benefits
    • Current Members and Life Sciences Industry
    • Current Members by Category
    • Profiled Company
      • Profiled Company
      • Previously Profiled Companies
  • Resources
    • Resources
    • Other Resources
  • Contact
Home Print This Page

General Intermediates Successfully Completes Government of Canada Funded Pharmaceutical Project

Edmonton's GIC Completes Research Program for a new API Starting Material

 

Edmonton’s General Intermediates of Canada Inc. (GIC) announced they have successfully completed a research project related to a key starting API material for a global pharmaceutical client.  This project was done with the support of the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP.)

 

GIC has taken the 2-chloro-5-hydroxy (2C5H) pyrimidine molecule and developed a novel synthesis route which enables the molecule to be manufactured economically, in commercial quantities, at purity levels not previously seen in the industry.   Although this molecule was long of interest to the global pharmaceutical industry, it was not economically feasible for commercialization prior to GIC’s work.

 

“In addition to helping our client with quality and repeatability regarding 2C5H, our work in process refinement and the production of difficult small molecules in metric tonne quantities has led to other contract manufacturing opportunities,” said Dr. Glenn Weagle.  “The support of IRAP was key to our success.”

 

Read full press release details.

Contact Us
Suite 202
10055 - 106 Street NW
Edmonton, Alberta T5J 2Y2
Canada
Ph:  780.425.3804
Fx:  780.409.9263
admin@BioAlberta.com
Quick Links
Home
About
Industry Facts
News
Events
Member Area
Publications
Contact
Return Policy
Privacy
Terms of Use
Connect
BioAlberta: Twitter linkBioAlberta: linkedin linkBioAlberta: YouTube linkBioAlberta: facebook link